Close Menu

NEW YORK – Promega said on Tuesday that it has received CE marking for its OncoMate MSI Dx Analysis System, allowing it to make the test available as an in vitro diagnostic medical device in Europe.

OncoMate MSI is a PCR-based assay that measures microsatellite instability status in tissue samples from solid tumors. According to Promega, the kit offers high analytical sensitivity and specificity with a short turnaround time.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports.

A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.

The New York Times reports Moderna is planning a clinical trial of its SARS-CoV-2 vaccine in children.

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.